Duke University

Children's Medical Center Corporation

University of Pennsylvania

University of California

Bristol-myers Squibb Compnay

The Government of the United States of America As Represented by the Secretary of the Deptartment of Health and Human Services

University of North Carolina at Chapel Hill

The Uab Research Foundation

US Government As Represented by the Secretary of the Army

Leland Stanford Junior University

University System of Maryland

Boston University

Other

New York University

Dana-farber-cancer Institute Inc.

Barton F Haynes

Hua-Xin Liao

Bette T Korber

Norman L Letvin

Beatrice H Hahn

M Anthony Moody

William M Fischer

Dhavalkumar D Patel

George M Shaw

Feng Gao

S Munir Alam

Mattia Bonsignori

Thomas B Kepler

Peter T Hraber

Guido Ferrari

Kevin J Wiehe

Leslie Sydnor Johnson

Scott Koenig

Stephen C Harrison

Chia-Ying Kao Lam

Liqin Liu

Michael J Campa

Jeffrey Lee Nordstrom

Elizabeth Gottlin

Kevin O Saunders

Edward F Patz, Jr

Jerome H Kim

Georgia D Tomaras

Thomas J Palker

Alejandro A Aruffo

Ying Ying Li

James Theiler

Nelson L Michael

Garnett Kelsoe

Simon J Perkins

Karina Yusim

Carla L Kuiken

Gregory D Sempowski

Julie Decker

Robert M De Lorimier

Munir Alam

Tanmoy Bhattacharya

Peter D Kwong

John R Mascola

Tongqing Zhou

Hans Marquardt

Michael A Bowen

Herman F Staats

David Margolis

Scott D Boyd

Rebecca M Lynch

Julia A Sung

David C Montefiori

LaTonya Williams

Gilad Adi Ofek

Denise Kothe

Gary J Nabel

Samuel J Danishefsky

William R Jacobs, Jr

Anthony W Siadak

Joseph G Sodroski

Susan Zolla-Pazner

John Mascola

Xueling Wu

J Brice Weinberg

Ronald I Swanstrom

Peter Kinam Park

Michael Anthony Moody

Laurent Verkoczy

Matt T Holl

Masayuki Kuraoka

Mark Cayabyab

Jae-Sung Yu

Avi-Hai Hovav

Aaron G Schmidt

Karen L Patton

Sallie Permar

Li-Hua Ping

Sandrasegaram Gnanakaran

Celia C Labranche

Rory Henderson

Ryan Meyerhoff

Todd Bradley

Baptiste Aussedat

Yusuf Vohra

Anthony M Moody

Huaxin Liao

James Whittle

Denise L Monti

Morgane Rolland

Moses D Sekaran

Xiaoying Shen

Disclosed herein are Complement factor H (CFH) inhibitors, such as anti-CFH antibodies and small molecules, and methods of using said inhibitors.

Inhibitors of complement factor H

The invention is directed to bispecific molecules comprising an HIV-1 envelope targeting arm and an arm targeting an effector cell, compositions comprising these bispecific molecule and methods of use. In certain aspects, the bispecific molecules of the present invention can bind to two different targets or epitopes on two different cells within the first epitope is expressed on a different cell type than the second epitope, such that the bispecific molecules can bring the two cells together. In certain aspects, the bispecific molecules of the present invention can bind to two different cells, wherein the bispecific molecules comprises an arm with the binding specificity of A32, 7B2, CH27, CH28 or CH44.

Bispecific molecules comprising an HIV-1 envelope targeting arm

The technology is directed to HIV envelopes which comprise sequence modifications wherein these modifications prevent CD4-induced transitions of the HIV envelope. Specifically, the disclosure provides recombinant HIV-1 Env proteins comprising mutations, wherein the envelope is a protomer, and wherein three protomers form a trimer stabilized by the presence of the mutations. Provided also are compositions comprising envelopes of the technology, and methods of use.

HIV-1 envelope stabilizing mutations

The invention is directed to HIV-1 neutralizing antibodies and methods for their uses.

HIV-1 neutralizing antibodies and uses thereof

Methods of inhibiting complement factor H (CFH) comprising administering an antibody that binds CFH

In certain aspects the invention provides HIV-1 immunogens, including HIV-1 envelope selections from individual CH505, and methods for swarm immunizations using combinations of HIV-1 envelopes.

Compositions comprising HIV envelopes to induce CH235 lineage antibodies

The invention is directed to immunogens and methods for inducing immune responses, comprising methods for germline B cell stimulation and maturation by reverse engineering of HIV-1 envelopes.

Compositions comprising modified HIV envelopes

The invention is directed to mosaic HIV-1 envelopes, and methods of using the same to induce ADCC responses.

Mosaic HIV-1 envelopes to induce ADCC responses

The invention is directed to methods to identify improbable mutations in the heavy or light chain variable domain of an antibody, methods to identify antigens which bind to antibodies comprising such improbable mutations, and methods of using such antigens to induce immune responses.

Methods to identify immunogens by targeting improbable mutations

The present invention relates to bispecific molecules that are capable of localizing an immune effector cell that expresses an activating receptor to a virally infected cell, so as to thereby facilitate the killing of the virally infected cell. In a preferred embodiment, such localization is accomplished using bispecific molecules that are immunoreactive with an activating receptor of an immune effector cell and to an antigen expressed by a cell infected with a virus wherein the antigen is detectably present on the cell infected with the virus at a level that is greater than the level at which the antigen is detected on the virus by the bispecific molecules, and to the use of such bispecific molecules in the treatment of latent viral infections.

Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof

In certain aspects the invention provides HV-1 immunogens, including envelopes (CH0848) and selections therefrom, and methods for swarm immunizations using combinations of HIV-1 envelopes.

Compositions and methods for inducing HIV-1 antibodies

In certain aspects the invention provides HIV-1 immunogens, including envelopes (CH0848) and selections there&#x2014;from, and methods for swarm immunizations using combinations of HIV-1 envelopes.

Anti-complement factor H antibodies

The invention provides compositions and methods to induce and boost antibody response, including but not limited to IgG responses binding to HIV-1 in a subject in need thereof, wherein the induced/boosted plasma level of the antibody responses, for example V3 and/or CD4 binding site antibody responses, is over a threshold level and is associated with reduced risk of maternal-to-child-transmission (MTCT) of HIV-1.

Methods for reducing HIV-1 mother-to-child transmission by inducing V3-specific or CD4 binding site-specific antibodies

Growing community of inventors

Durham, NC, United States of America

Barton F Haynes